A new app developed by Cornell computer science researchers helps users record highly accurate time-lapse videos of body parts – a surprisingly difficult task and an unmet need in remote medicine and telehealth applications.
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
Faculty and staff within Cornell’s Department of Public & Ecosystem Health have been funded by the U.S. Centers for Disease Control and Prevention’s (CDC) National Center for State, Tribal, Local, and Territorial Public Health Infrastructure and Workforce to help strengthen the public health system in the United States.
An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.
Inhibiting an immune signaling protein may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer’s disease and ordinary aging, a new study suggests.
A ceremonial ribbon-cutting on May 1 formally welcomed the Feil Family and Weill Family Residence Hall, located at the northwest corner of 74th Street and York Avenue, into Weill Cornell Medicine’s main campus.
The hormone estrogen regulates binge drinking in females, causing them to “pregame” – consume large quantities of alcohol in the first 30 minutes after it’s offered, according to a preclinical study led by scientists at Weill Cornell Medicine.
Weill Cornell Medicine researchers have determined the full-length structure and function of a blood pressure-regulating hormone receptor, which may enable better drug targeting of the receptor for diseases such as hypertension and heart failure.
A new protocol can detect and remove fake data created by bots and humans attempting to enroll in online research studies, in order to prevent biased results and unwarranted payments to bad actors – the first such protocol specifically designed for data collected in rural communities.
The new injectable weight-loss drug reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo.